Brian ODonoghue
Overview
Explore the profile of Brian ODonoghue including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
1414
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zierotin A, Norton M, ODonoghue B, OConnor K, Clarke M
Ir J Psychol Med
. 2025 Feb;
:1-7.
PMID: 39901594
This paper explores the intersection of physical health and recovery-oriented approaches in psychosis, offering a unique perspective through autoethnography. By combining personal experience with a broader analysis of existing mental...
2.
Zierotin A, Murphy J, ODonoghue B, OConnor K, Norton M, Clarke M
HRB Open Res
. 2025 Jan;
6:75.
PMID: 39867518
Background: Individuals with first-episode psychosis (FEP) face an increased risk of physical comorbidities, notably cardiovascular diseases, metabolic disorders, respiratory disorders, and certain types of cancer. Previous reviews report pooled physical...
3.
Verdoux H, Bittner R, Hasan A, Qubad M, Wagner E, Lepetit A, et al.
Eur Psychiatry
. 2025 Jan;
68(1):e17.
PMID: 39788917
The European Clozapine Task Force is a group of psychiatrists and pharmacologists practicing in 18 countries under European Medicines Agency (EMA) regulation, who are deeply concerned about the underuse of...
4.
Carolan A, Hynes-Ryan C, Agarwal S, Bourke R, Cullen W, Gaughran F, et al.
Schizophr Bull
. 2024 Dec;
PMID: 39657713
Background: Overweight and obesity are highly prevalent in people with severe mental illness (SMI). Antipsychotic-induced weight gain (AIWG) is one of the most commonly reported and distressing side effects of...
5.
FitzPatrick P, Brown E, Street R, ODonoghue B
Ir J Psychol Med
. 2024 Dec;
:1-7.
PMID: 39639528
Objectives: Suicide accounts for a proportion of the early mortality in people affected by psychotic disorders. The early phase of illness can represent a particularly high-risk time for suicide. Therefore,...
6.
ODonoghue B, Oliver D, Geros H, Sizer H, Thompson A, McGorry P, et al.
Psychol Med
. 2024 Nov;
:1-9.
PMID: 39582387
Background And Hypothesis: Transition to psychosis rates within ultra-high risk (UHR) services have been declining. It may be possible to 'enrich' UHR cohorts based on the environmental characteristics seen more...
7.
Cotter S, Smith C, Gao C, Khanna R, ODonoghue B, Brown E, et al.
Schizophr Res
. 2024 Aug;
272:79-88.
PMID: 39208768
Background: In Australia, the first nationwide COVID-19 lockdown occurred in March 2020 bringing challenges for early intervention psychosis (EIP) services. Limited evidence exists on the impacts of the pandemic on...
8.
Chopra S, Levi P, Holmes A, Orchard E, Segal A, Francey S, et al.
Biol Psychiatry
. 2024 Jul;
97(2):157-166.
PMID: 39069164
Background: Disruptions of axonal connectivity are thought to be a core pathophysiological feature of psychotic illness, but whether they are present early in the illness, prior to antipsychotic exposure, and...
9.
Murphy J, Zierotin A, Mongan D, Healy C, R Susai S, ODonoghue B, et al.
Brain Behav Immun
. 2024 Jun;
120():327-338.
PMID: 38857636
Background: There is some evidence of an association between inflammation in the pathogenesis of mental disorders. Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker of chronic inflammation, which provides...
10.
Yu O, Lu M, Lai T, Hahn M, Agarwal S, ODonoghue B, et al.
Ther Adv Psychopharmacol
. 2024 Jun;
14:20451253241255476.
PMID: 38827016
Background: Antipsychotic medications are associated with weight gain and metabolic derangement. However, comprehensive evidence for the efficacy of co-commenced pharmacological treatments to mitigate initial weight gain is limited. Metformin has...